Background 3-Hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have already been widely used to lessen cardiovascular risk. vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) manifestation. SQ22536, an inhibitor of adenylate cyclase, markedly reversed the simvastatin-mediated inhibitory results on platelet aggregation, PLC2 and p38 MAPK phosphorylation, and simvastatin-mediated stimulatory results on VASP and… Continue reading Background 3-Hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have already been